semaglutide and cardiovascular outcomes in patients with type 2 diabetes trials: a paradigm shift the current management of | Cardiovascular Diabetology Cardiovascular Outcomes, Safety, and Tolerability

& Jones, M

The FDA-approved prescribing information for semaglutide does not list hepatotoxicity as a recognized adverse effect, and large-scale clinical trials have not demonstrated an increased risk of liver injury compared to placebo or other diabetes medications

The approach here has been to recognize that neonatal hyperbilirubinemia may be caused by G6PD deficiency and these children should be tested and monitored closely

In the USA, the monthly average cost of following Wegovy treatment is more than $1300 per month without insurance coverage

Hyperglycemia acutely lowers the postprandial excursions of glucagon-like peptide-1 and gastric inhibitory polypeptide in humans

Compounded semaglutide from PlexusDx is $189 per month month-to-month, or from $149/mo on the 6-month plan with no flat per-compound pricing increases